Literature DB >> 21827804

Effect of the E-selectin gene polymorphism (S149R) on platelet activation and adverse events after coronary artery surgery.

Ewa Stępień1, Sylwia Krawczyk, Bogusław Kapelak, Robert Sobczyński, Jarosław Stoliński, Ewa Wypasek, Anetta Undas, Jerzy Sadowski.   

Abstract

BACKGROUND AND AIMS: A common single nucleotide polymorphism in the E-selectin (SELE) gene S149R results in the loss of E-selectin ligand binding specificity. The 149R allele has been associated with severe cardiovascular diseases. We hypothesized that S149R may regulate platelet activation after stimuli associated with perioperative procedures in patients undergoing isolated coronary artery bypass grafting (CABG). Associations between the S149R polymorphism and an increased risk of perioperative acute thrombotic events with regards to a platelet count and activity were analyzed.
METHODS: In elective CABG patients (n = 152) we analyzed associations between S149R polymorphism and an increased risk of perioperative acute thrombotic events with regard to platelet count and activity. The S149R SELE gene polymorphism was determined by real-time polymerase chain reaction. Platelet count and activation marker (β-thromboglobulin-βTG) were evaluated.
RESULTS: Prevalence of the S149R genotypes was as follows: 81.8% (n = 121) of homozygotes (149SS), 15.5% (n = 23) of heterozygotes and 2.7% (n = 4) of homozygotes (149RR). The 149R allele carriers had significantly higher postoperative βTG levels than the homozygotes (97 [79-120] vs. 76 [66-91] IU/mL, p = 0.03). Sixteen patients had adverse events: myocardial infarction (n = 14), stroke (n = 1) and fatal pulmonary embolism (n = 1). Twelve patients were carriers of the 149R allele. Relative risk (RR) of postoperative adverse events in the 149R allele carriers was 2.03 with 95% CI (1.05-3.03).
CONCLUSIONS: Postoperative platelet activation is related to the S149R polymorphism, which enhances the risk of adverse events after CABG.
Copyright © 2011 IMSS. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21827804     DOI: 10.1016/j.arcmed.2011.07.007

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  6 in total

1.  Implications of the E-selectin S128R mutation for drug discovery.

Authors:  Roland C Preston; Said Rabbani; Florian P C Binder; Suzette Moes; John L Magnani; Beat Ernst
Journal:  Glycobiology       Date:  2014-03-31       Impact factor: 4.313

2.  Correlations of SELE genetic polymorphisms with risk of coronary heart disease and myocardial infarction: a meta-analysis.

Authors:  Zhao-Qiang Dong; Xiang-Jun Wu; Qing-Hua Lu
Journal:  Mol Biol Rep       Date:  2014-01-24       Impact factor: 2.316

3.  Correlations of SELE and SELP genetic polymorphisms with myocardial infarction risk: a meta-analysis and meta-regression.

Authors:  Yu-Juan Zhao; Xia Yang; Li Ren; An-Sheng Cai; Yan-Fen Zhang
Journal:  Mol Biol Rep       Date:  2014-03-18       Impact factor: 2.316

4.  Polymorphisms in glutathione S-transferase are risk factors for perioperative acute myocardial infarction after cardiac surgery: a preliminary study.

Authors:  Viktória Kovacs; Balazs Gasz; Borbala Balatonyi; Luca Jaromi; Peter Kisfali; Balazs Borsiczky; Gabor Jancso; Nandor Marczin; Sandor Szabados; Bela Melegh; Alotti Nasri; Elisabeth Roth
Journal:  Mol Cell Biochem       Date:  2014-01-17       Impact factor: 3.396

Review 5.  Relationship of SELE A561C and G98T Variants With the Susceptibility to CAD.

Authors:  Bihong Liao; Keqi Chen; Wei Xiong; Ruimian Chen; Aihuan Mai; Zhenglei Xu; Shaohong Dong
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

Review 6.  Biomarkers in Coronary Artery Bypass Surgery: Ready for Prime Time and Outcome Prediction?

Authors:  Alessandro Parolari; Paolo Poggio; Veronika Myasoedova; Paola Songia; Giorgia Bonalumi; Alberto Pilozzi; Davide Pacini; Francesco Alamanni; Elena Tremoli
Journal:  Front Cardiovasc Med       Date:  2016-01-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.